Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2592
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials” ; volume:37 ; number:8 ; day:5 ; month:9 ; year:2017 ; pages:739-740 ; date:11.2017
Journal of clinical immunology ; 37, Heft 8 (5.9.2017), 739-740, 11.2017
- Keyword
-
Nichtmedikamentöse Therapie
- Creator
-
Suez, Daniel
- Contributor
-
Stein, Mark
Gupta, Sudhir
Hussain, Iftikhar
Melamed, Isaac
Paris, Kenneth
Darter, Amy
Bourgeois, Christelle
Fritsch, Sandor
Leibl, Heinz
McCoy, Barbara
Gelmont, David
Yel, Leman
SpringerLink (Online service)
- DOI
-
10.1007/s10875-017-0438-y
- URN
-
urn:nbn:de:1111-201712214589
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Suez, Daniel
- Stein, Mark
- Gupta, Sudhir
- Hussain, Iftikhar
- Melamed, Isaac
- Paris, Kenneth
- Darter, Amy
- Bourgeois, Christelle
- Fritsch, Sandor
- Leibl, Heinz
- McCoy, Barbara
- Gelmont, David
- Yel, Leman
- SpringerLink (Online service)
Other Objects (12)
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
New Frontiers in Subcutaneous Immunoglobulin Treatment
A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
To the Editor
Letter to Editor
To the Editor
To the Editor
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
New Frontiers in Subcutaneous Immunoglobulin Treatment
A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
To the Editor
Letter to Editor
To the Editor
To the Editor
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
New Frontiers in Subcutaneous Immunoglobulin Treatment
A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
To the Editor
Letter to Editor
To the Editor